BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cao X, Wang Y, Li P, Huang W, Lu X, Lu H. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021;11:685706. [PMID: 34277431 DOI: 10.3389/fonc.2021.685706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Nuersulitan R, Zhang C, Na H, Li J, Song Y, Zhu J, Wang G, Liu W, Zhao H. Steadily decline of HBV DNA load under NAs in lymphoma patients and higher level of qAnti-HBc predict HBV reactivation.. [DOI: 10.21203/rs.3.rs-2596830/v1] [Reference Citation Analysis]
2 Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, Kao JH, Terrault N, Lok AS, Reddy KR. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol 2022;77:1670-89. [PMID: 35850281 DOI: 10.1016/j.jhep.2022.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Elsebaey MA, Elbedewy TA, Elashry H, Elrefaey W, Elshweikh SA, Elhadidy AA, Shalaby NA, Elsokkary AM, Elashtokhy HEA, Abo-Amer YE, Abo-Elfetoh AR, Hassanien SEA, Fouad A, Abdellatif RS, Ismail AAM. Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation. Medicine (Baltimore) 2022;101:e31962. [PMID: 36451458 DOI: 10.1097/MD.0000000000031962] [Reference Citation Analysis]
4 Song Z, Ma Y, Jiang D, Zhao R, Dong F. Long-Term Safety of Rituximab in DLBCL Patients With Hepatitis B-Related Cirrhosis: A Retrospective Case Series. Front Med (Lausanne) 2022;9:890339. [PMID: 35712098 DOI: 10.3389/fmed.2022.890339] [Reference Citation Analysis]
5 Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.02.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Ackerman RS, Muncey AR, Aldawoodi NN, Kotha R, Getting REG. Cancer Immunotherapies: What the Perioperative Physician Needs to Know. Curr Oncol Rep 2022. [PMID: 35141856 DOI: 10.1007/s11912-022-01202-6] [Reference Citation Analysis]
7 Huang W, Du L, Tang H. Hepatitis B virus reactivation: overview and management. Future Virology 2021;16:821-35. [DOI: 10.2217/fvl-2021-0275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Watanabe T, Inoue T, Tanaka Y. Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. Microorganisms 2021;9:2083. [PMID: 34683404 DOI: 10.3390/microorganisms9102083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 宣 碧. HBV Reactivation in Patients with HBsAg(-)/HBcAb(+) Induced by Rituximab Combined with Chemotherapy: A Case Report and Literature Review. ACM 2021;11:5224-5229. [DOI: 10.12677/acm.2021.1111771] [Reference Citation Analysis]